{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,19]],"date-time":"2026-07-19T03:30:38Z","timestamp":1784431838914,"version":"3.55.0"},"reference-count":94,"publisher":"BMJ","issue":"5","license":[{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"unspecified","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2026,4,18]]},"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chimeric antigen receptor (CAR) therapies have revolutionized cancer immunotherapy, particularly in hematologic malignancies, but their efficacy in solid tumors remains limited. Key barriers include tumor antigen heterogeneity, on-target\/off-tumor toxicity, impaired trafficking, and an immunosuppressive tumor microenvironment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a narrative review of preclinical and clinical studies investigating CAR-engineered innate and innate-like immune cells, including CAR-natural killer, CAR-\u03b3\u03b4 T, CAR-natural killer T (NKT), and CAR-macrophages, focusing on their biological features, therapeutic potential, and current clinical development in solid tumors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>These alternative platforms exhibit distinct advantages over conventional CAR-T cells, including reduced risk of severe toxicities, improved trafficking, overcoming antigen loss, and higher allogeneic potential. Emerging clinical data suggest favorable safety profiles, although limited persistence and variable efficacy remain key challenges. Advances in cell engineering, such as cytokine armoring and non-viral gene transfer, are further enhancing their therapeutic potential.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>CAR-engineered innate and innate-like immune cells represent a promising next-generation strategy to overcome the limitations of conventional CAR-T therapies in solid tumors. Among these, CAR-NKT and CAR-\u03b3\u03b4 T cells may offer particular advantages for clinical translation, warranting further investigation in future trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2025-014592","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T17:15:19Z","timestamp":1777914919000},"page":"e014592","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["CAR-engineering of innate and innate-like immune cells: a new horizon in adoptive cell therapy for solid tumors"],"prefix":"10.1136","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct03373097","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04196413","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01869166","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03182816","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01935843","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00902044","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02932956","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04715191","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05103631","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03873805","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02744287","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01583686","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02414269","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01355965","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03198546","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03874897","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02850536","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03089203","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02706392","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06043466","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02541370","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04438083","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03060356","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03294954","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03415100","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03656705","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04050709","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04390399","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03941457","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03383978","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03692663","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02839954","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06562647","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04660929","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05239143","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03692429","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04991948","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03825718","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03692663","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05507593","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03294954","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04911478","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04735471","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06150885","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05302037","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04107142","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-2085-8882","authenticated-orcid":false,"given":"Giuseppe","family":"Nardo","sequence":"first","affiliation":[{"name":"Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8876-0586","authenticated-orcid":false,"given":"Francesca","family":"Putti","sequence":"additional","affiliation":[{"name":"Unit of Immunotherapy and Anticancer Innovative Therapeutics, Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8686-4106","authenticated-orcid":false,"given":"Alice","family":"Indini","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"},{"name":"Unit of Melanoma Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9060-2512","authenticated-orcid":false,"given":"Michele","family":"Del Vecchio","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"},{"name":"Unit of Melanoma Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0103-730X","authenticated-orcid":false,"given":"Filippo","family":"De Braud","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"},{"name":"Medical Oncology and Hematology Department, University of Milan, Milan, Italy"},{"name":"Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Di Nicola","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"},{"name":"Unit of Immunotherapy and Anticancer Innovative Therapeutics, Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5877-0639","authenticated-orcid":false,"given":"Francesca","family":"De Santis","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"},{"name":"Unit of Immunotherapy and Anticancer Innovative Therapeutics, Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,5,4]]},"reference":[{"key":"2026050410150952000_14.5.e014592.1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1835"},{"key":"2026050410150952000_14.5.e014592.2","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.693016","article-title":"CAR-T cell therapy: mechanism, management, and mitigation of inflammatory toxicities","volume":"12","author":"Fischer","year":"2021","journal-title":"Front Immunol"},{"key":"2026050410150952000_14.5.e014592.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1610497"},{"key":"2026050410150952000_14.5.e014592.4","doi-asserted-by":"publisher","DOI":"10.1172\/JCI32446"},{"key":"2026050410150952000_14.5.e014592.5","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s13046-019-1153-8","article-title":"Therapeutic challenges and current immunomodulatory strategies in targeting the immunosuppressive pancreatic tumor microenvironment","volume":"38","author":"Looi","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"key":"2026050410150952000_14.5.e014592.6","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/6616391","article-title":"T cell exhaustion and CAR-T immunotherapy in hematological malignancies","volume":"2021","author":"Tang","year":"2021","journal-title":"Biomed Res Int"},{"key":"2026050410150952000_14.5.e014592.7","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1811"},{"key":"2026050410150952000_14.5.e014592.8","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008659","article-title":"Safety and biological outcomes following a phase 1 trial of GD2-specific CAR-T cells in patients with GD2-positive metastatic melanoma and other solid cancers","volume":"12","author":"Gargett","year":"2024","journal-title":"J Immunother Cancer"},{"key":"2026050410150952000_14.5.e014592.9","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1016\/j.ymthe.2022.06.006","article-title":"Universal allogeneic CAR T cells engineered with Sleeping Beauty transposons and CRISPR-Cas9 for cancer immunotherapy","volume":"30","author":"Tipanee","year":"2022","journal-title":"Mol Ther"},{"key":"2026050410150952000_14.5.e014592.10","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30896-2"},{"key":"2026050410150952000_14.5.e014592.11","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006239","article-title":"IL15 modification enables CAR T cells to act as a dual targeting agent against tumor cells and myeloid-derived suppressor cells in GBM","volume":"11","author":"Zannikou","year":"2023","journal-title":"J Immunother Cancer"},{"key":"2026050410150952000_14.5.e014592.12","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1166169","article-title":"Specific and safe targeting of glioblastoma using switchable and logic-gated RevCAR T cells","volume":"14","author":"Saleh","year":"2023","journal-title":"Front Immunol"},{"key":"2026050410150952000_14.5.e014592.13","first-page":"103489","article-title":"Accelerating CAR T cell manufacturing with an automated next-day process","volume":"73","author":"Ahmadi","year":"2025","journal-title":"Curr Res Transl Med"},{"key":"2026050410150952000_14.5.e014592.14","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-022-00694-6","article-title":"Next-day manufacture of a novel anti-CD19 CAR-T therapy for B-cell acute lymphoblastic leukemia: first-in-human clinical study","volume":"12","author":"Yang","year":"2022","journal-title":"Blood Cancer J"},{"key":"2026050410150952000_14.5.e014592.15","first-page":"1083","article-title":"First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia","volume":"8","author":"Tang","year":"2018","journal-title":"Am J Cancer Res"},{"key":"2026050410150952000_14.5.e014592.16","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01376-3"},{"key":"2026050410150952000_14.5.e014592.17","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.586168","article-title":"HLA class I knockout converts allogeneic primary NK cells into suitable effectors for \u201coff-the-shelf\u201d immunotherapy","volume":"11","author":"Hoerster","year":"2020","journal-title":"Front Immunol"},{"key":"2026050410150952000_14.5.e014592.18","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008155","article-title":"CAR-mediated targeting of NK cells overcomes tumor immune escape caused by ICAM-1 downregulation","volume":"12","author":"Eitler","year":"2024","journal-title":"J Immunother Cancer"},{"key":"2026050410150952000_14.5.e014592.19","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.102619","article-title":"Expanded human NK cells armed with CAR uncouple potent anti-tumor activity from off-tumor toxicity against solid tumors","volume":"24","author":"Portillo","year":"2021","journal-title":"iScience"},{"key":"2026050410150952000_14.5.e014592.20","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02785-8"},{"key":"2026050410150952000_14.5.e014592.21","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.226"},{"key":"2026050410150952000_14.5.e014592.22","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15174310","article-title":"Co-expression of an IL-15 superagonist facilitates self-enrichment of GD2-targeted CAR-NK cells and mediates potent cell killing in the absence of IL-2","volume":"15","author":"Bodden","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2026050410150952000_14.5.e014592.23","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.omtm.2021.10.014","article-title":"piggyBac system to co-express NKG2D CAR and IL-15 to augment the in vivo persistence and anti-AML activity of human peripheral blood NK cells","volume":"23","author":"Du","year":"2021","journal-title":"Molecular Therapy - Methods & Clinical Development"},{"key":"2026050410150952000_14.5.e014592.24","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1226518","article-title":"Engineering NK-CAR.19 cells with the IL-15\/IL-15R\u03b1 complex improved proliferation and anti-tumor effect in vivo","volume":"14","author":"Silvestre","year":"2023","journal-title":"Front Immunol"},{"key":"2026050410150952000_14.5.e014592.25","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1182\/bloodadvances.2023012202","article-title":"CD70-specific CAR NK cells expressing IL-15 for the treatment of CD19-negative B-cell malignancy","volume":"8","author":"Guo","year":"2024","journal-title":"Blood Adv"},{"key":"2026050410150952000_14.5.e014592.26","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-023-11806-1","article-title":"Co-expression of IL-21-Enhanced NKG2D CAR-NK cell therapy for lung cancer","volume":"24","author":"Zhang","year":"2024","journal-title":"BMC Cancer"},{"key":"2026050410150952000_14.5.e014592.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2024.07.007"},{"key":"2026050410150952000_14.5.e014592.28","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13045-024-01525-w","article-title":"IL-15-secreting CAR natural killer cells directed toward the pan-cancer target CD70 eliminate both cancer cells and cancer-associated fibroblasts","volume":"17","author":"Van den Eynde","year":"2024","journal-title":"J Hematol Oncol"},{"key":"2026050410150952000_14.5.e014592.29","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41392-025-02158-2","article-title":"Neoleukin-2\/15-armored CAR-NK cells sustain superior therapeutic efficacy in solid tumors via c-Myc\/NRF1 activation","volume":"10","author":"Luo","year":"2025","journal-title":"Sig Transduct Target Ther"},{"key":"2026050410150952000_14.5.e014592.30","doi-asserted-by":"crossref","unstructured":"Li L , Mohanty V , Dou J , et al . Loss of metabolic fitness drives tumor resistance after CAR-NK cell therapy and can be overcome by cytokine engineering. Sci Adv 2023;9. doi:10.1126\/sciadv.add6997","DOI":"10.1126\/sciadv.add6997"},{"key":"2026050410150952000_14.5.e014592.31","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.molimm.2023.01.010","article-title":"Engagement of an optimized lentiviral vector enhances the expression and cytotoxicity of CAR in human NK cells","volume":"155","author":"Guo","year":"2023","journal-title":"Mol Immunol"},{"key":"2026050410150952000_14.5.e014592.32","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.751138","article-title":"Generation of an NF\u03baB-Driven Alpharetroviral \u201cAll-in-One\u201d Vector Construct as a Potent Tool for CAR NK Cell Therapy","volume":"12","author":"Rudek","year":"2021","journal-title":"Front Immunol"},{"key":"2026050410150952000_14.5.e014592.33","doi-asserted-by":"crossref","DOI":"10.1016\/j.crmeth.2022.100236","article-title":"Optimization and validation of CAR transduction into human primary NK cells using CRISPR and AAV","volume":"2","author":"Naeimi Kararoudi","year":"2022","journal-title":"Cell Rep Methods"},{"key":"2026050410150952000_14.5.e014592.34","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1016\/j.ymthe.2024.05.022","article-title":"Engineering of potent CAR NK cells using non-viral Sleeping Beauty transposition from minimalistic DNA vectors","volume":"32","author":"Bexte","year":"2024","journal-title":"Mol Ther"},{"key":"2026050410150952000_14.5.e014592.35","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/978-1-0716-3593-3_18","article-title":"A nonviral piggyBac transposon-mediated method to generate large-scale CAR-NK cells from human peripheral blood primary NK cells","volume":"2748","author":"Du","year":"2024","journal-title":"Methods Mol Biol Clifton NJ"},{"key":"2026050410150952000_14.5.e014592.36","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/978-1-0716-3770-8_10","article-title":"Electroporation of mRNA as a universal technology platform to transfect a variety of primary cells with antigens and functional proteins","volume":"2786","author":"Sauerer","year":"2024","journal-title":"Methods Mol Biol Clifton NJ"},{"key":"2026050410150952000_14.5.e014592.37","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241713364","article-title":"CAR-NK cells generated with mRNA-LNPs kill tumor target cells in vitro and in vivo","volume":"24","author":"Golubovskaya","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2026050410150952000_14.5.e014592.38","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02003-x"},{"key":"2026050410150952000_14.5.e014592.39","doi-asserted-by":"crossref","first-page":"1081546","DOI":"10.3389\/fimmu.2022.1081546","article-title":"Clinical application and prospect of immune checkpoint inhibitors for CAR-NK cell in tumor immunotherapy","volume":"13","author":"Yang","year":"2022","journal-title":"Front Immunol"},{"key":"2026050410150952000_14.5.e014592.40","doi-asserted-by":"crossref","DOI":"10.1186\/s40164-024-00522-6","article-title":"CAR T cells outperform CAR NK cells in CAR-mediated effector functions in head-to-head comparison","volume":"13","author":"Egli","year":"2024","journal-title":"Exp Hematol Oncol"},{"key":"2026050410150952000_14.5.e014592.41","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-025-13780-2","article-title":"CAR-NK cells with dual targeting of PD-L1 and MICA\/B in lung cancer tumor models","volume":"25","author":"Zhi","year":"2025","journal-title":"BMC Cancer"},{"key":"2026050410150952000_14.5.e014592.42","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1533044","article-title":"Entinostat, a histone deacetylase inhibitor, enhances CAR-NK cell anti-tumor activity by sustaining CAR expression","volume":"16","author":"Jo","year":"2025","journal-title":"Front Immunol"},{"key":"2026050410150952000_14.5.e014592.43","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/CJI.0000000000000483","article-title":"Mesothelin-targeted CAR-NK cells derived from induced pluripotent stem cells have high efficacy in killing triple-negative breast cancer cells in preclinical models","volume":"46","author":"Yang","year":"2023","journal-title":"J Immunother"},{"key":"2026050410150952000_14.5.e014592.44","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.64630"},{"key":"2026050410150952000_14.5.e014592.45","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1485461","article-title":"Anti-Mesothelin CAR-NK cells as a novel targeted therapy against cervical cancer","volume":"15","author":"Kutle","year":"2024","journal-title":"Front Immunol"},{"key":"2026050410150952000_14.5.e014592.46","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.3389\/fphar.2020.01089","article-title":"Targeting B7-H3 immune checkpoint with chimeric antigen receptor-engineered natural killer cells exhibits potent cytotoxicity against non-small cell lung cancer","volume":"11","author":"Yang","year":"2020","journal-title":"Front Pharmacol"},{"key":"2026050410150952000_14.5.e014592.47","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.omtm.2022.10.010","article-title":"Co-transducing B7H3 CAR-NK cells with the DNR preserves their cytolytic function against GBM in the presence of exogenous TGF-\u03b2","volume":"27","author":"Chaudhry","year":"2022","journal-title":"Mol Ther Methods Clin Dev"},{"key":"2026050410150952000_14.5.e014592.48","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1007\/s13402-023-00842-5","article-title":"Therapeutic effects against high-grade glioblastoma mediated by engineered induced neural stem cells combined with GD2-specific CAR-NK","volume":"46","author":"Liu","year":"2023","journal-title":"Cell Oncol"},{"key":"2026050410150952000_14.5.e014592.49","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2022.2127508","article-title":"AAV-mediated gene transfer of a checkpoint inhibitor in combination with HER2-targeted CAR-NK cells as experimental therapy for glioblastoma","volume":"11","author":"Strecker","year":"2022","journal-title":"Oncoimmunology"},{"key":"2026050410150952000_14.5.e014592.50","doi-asserted-by":"crossref","DOI":"10.3390\/cells13030246","article-title":"Dual targeting of glioblastoma cells with bispecific killer cell engagers directed to EGFR and ErbB2 (HER2) facilitates effective elimination by NKG2D-CAR-engineered NK cells","volume":"13","author":"Kiefer","year":"2024","journal-title":"Cells"},{"key":"2026050410150952000_14.5.e014592.51","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1038\/s41416-025-02977-8","article-title":"CAR-NK cell therapy combined with checkpoint inhibition induces an NKT cell response in glioblastoma","volume":"132","author":"Strassheimer","year":"2025","journal-title":"Br J Cancer"},{"key":"2026050410150952000_14.5.e014592.52","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17050731","article-title":"Targeting HER2-positive solid tumors with CAR NK cells: CD44 expression is a critical modulator of HER2-specific CAR NK cell efficacy","volume":"17","author":"Gergely","year":"2025","journal-title":"Cancers (Basel)"},{"key":"2026050410150952000_14.5.e014592.53","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16020388","article-title":"Next-generation CEA-CAR-NK-92 cells against solid tumors: overcoming tumor microenvironment challenges in colorectal cancer","volume":"16","author":"Franz\u00e9n","year":"2024","journal-title":"Cancers (Basel)"},{"key":"2026050410150952000_14.5.e014592.54","doi-asserted-by":"crossref","unstructured":"Cao B , Ni Q , Chen Z , et al . Development of GPC3-CAR-NK cells and optimization as a therapy for HCC. J Leukoc Biol 2024.:qiae144. doi:10.1093\/jleuko\/qiae144","DOI":"10.1093\/jleuko\/qiae144"},{"key":"2026050410150952000_14.5.e014592.55","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.901","article-title":"Combined treatment with anti-PSMA CAR NK-92 cell and anti-PD-L1 monoclonal antibody enhances the antitumour efficacy against castration-resistant prostate cancer","volume":"12","author":"Wang","year":"2022","journal-title":"Clin Transl Med"},{"key":"2026050410150952000_14.5.e014592.56","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1002\/JLB.5MA0122-467R","article-title":"CAR NK-92 cells targeting DLL3 kill effectively small cell lung cancer cells in vitro and in vivo","volume":"112","author":"Liu","year":"2022","journal-title":"J Leukoc Biol"},{"key":"2026050410150952000_14.5.e014592.57","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1038\/s43018-024-00830-0","article-title":"CAR-redirected natural killer T cells demonstrate superior antitumor activity to CAR-T cells through multimodal CD1d-dependent mechanisms","volume":"5","author":"Zhou","year":"2024","journal-title":"Nat Cancer"},{"key":"2026050410150952000_14.5.e014592.58","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0161820","article-title":"Co-expansion of cytokine-induced killer cells and V\u03b39V\u03b42 T cells for CAR T-cell therapy","volume":"11","author":"Du","year":"2016","journal-title":"PLoS One"},{"key":"2026050410150952000_14.5.e014592.59","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.12.001"},{"key":"2026050410150952000_14.5.e014592.60","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.jcyt.2017.12.014","article-title":"Large-scale expansion of V\u03b39V\u03b42 T cells with engineered K562 feeder cells in G-Rex vessels and their use as chimeric antigen receptor-modified effector cells","volume":"20","author":"Xiao","year":"2018","journal-title":"Cytotherapy"},{"key":"2026050410150952000_14.5.e014592.61","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.15422"},{"key":"2026050410150952000_14.5.e014592.62","doi-asserted-by":"crossref","unstructured":"Bridge J , Johnson MJ , Kim J , et al . Efficient multiplex non-viral engineering and expansion of polyclonal \u03b3\u03b4 car-t cells for immunotherapy. Immunology [Preprint]. doi:10.1101\/2024.09.03.611042","DOI":"10.1101\/2024.09.03.611042"},{"key":"2026050410150952000_14.5.e014592.63","doi-asserted-by":"crossref","first-page":"10873","DOI":"10.3390\/ijms241310873","article-title":"CAR-modified V\u03b39V\u03b42 T cells propagated using a novel bisphosphonate prodrug for allogeneic adoptive immunotherapy","volume":"24","author":"Wang","year":"2023","journal-title":"IJMS"},{"key":"2026050410150952000_14.5.e014592.64","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.863155","article-title":"A simple and robust single-step method for CAR-V\u03b41 \u03b3\u03b4T cell expansion and transduction for cancer immunotherapy","volume":"13","author":"Ferry","year":"2022","journal-title":"Front Immunol"},{"key":"2026050410150952000_14.5.e014592.65","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.omto.2020.04.013","article-title":"Electroporation of NKG2D RNA CAR improves V\u03b39V\u03b42 T cell responses against human solid tumor xenografts","volume":"17","author":"Ang","year":"2020","journal-title":"Mol Ther Oncolytics"},{"key":"2026050410150952000_14.5.e014592.66","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.omto.2023.08.003","article-title":"Enhancing the effectiveness of \u03b3\u03b4 T cells by mRNA transfection of chimeric antigen receptors or bispecific T cell engagers","volume":"30","author":"Anderson","year":"2023","journal-title":"Mol Ther Oncolytics"},{"key":"2026050410150952000_14.5.e014592.67","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/j.jcyt.2024.03.025","article-title":"Genetic engineering of gamma delta (\u03b3\u03b4) T cells with the IL-2 cytokine receptor orthogonal pair (OIL-2R\/OIL-2) as immunotherapy for pediatric acute myeloid leukemia (AML)","volume":"26","author":"Wang","year":"2024","journal-title":"Cytotherapy"},{"key":"2026050410150952000_14.5.e014592.68","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-017-3539-3","article-title":"RNA-transfection of \u03b3\/\u03b4 T cells with a chimeric antigen receptor or an \u03b1\/\u03b2 T-cell receptor: a safer alternative to genetically engineered \u03b1\/\u03b2 T cells for the immunotherapy of melanoma","volume":"17","author":"Harrer","year":"2017","journal-title":"BMC Cancer"},{"key":"2026050410150952000_14.5.e014592.69","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003441","article-title":"Off-the-shelf V\u03b41 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma","volume":"9","author":"Makkouk","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2026050410150952000_14.5.e014592.70","doi-asserted-by":"crossref","first-page":"998","DOI":"10.3390\/cancers17060998","article-title":"CAR-\u03b3\u03b4 T cells targeting claudin18.2 show superior cytotoxicity against solid tumor compared to traditional CAR-\u03b1\u03b2 T cells","volume":"17","author":"Zhao","year":"2025","journal-title":"Cancers (Basel)"},{"key":"2026050410150952000_14.5.e014592.71","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42619-2"},{"key":"2026050410150952000_14.5.e014592.72","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1186\/s12967-023-04514-8","article-title":"B7H3-targeting chimeric antigen receptor modification enhances antitumor effect of V\u03b39V\u03b42 T cells in glioblastoma","volume":"21","author":"Wang","year":"2023","journal-title":"J Transl Med"},{"key":"2026050410150952000_14.5.e014592.73","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2019.01512","article-title":"Evaluating the polarization of tumor-associated macrophages into M1 and M2 phenotypes in human cancer tissue: technicalities and challenges in routine clinical practice","volume":"9","author":"Jayasingam","year":"2019","journal-title":"Front Oncol"},{"key":"2026050410150952000_14.5.e014592.74","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/jlb.64.4.419","article-title":"Adoptive immunotherapy of cancer using monocyte-derived macrophages: rationale, current status, and perspectives","volume":"64","author":"Andreesen","year":"1998","journal-title":"J Leukoc Biol"},{"key":"2026050410150952000_14.5.e014592.75","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-020-0462-y"},{"key":"2026050410150952000_14.5.e014592.76","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.stemcr.2022.12.012","article-title":"Generation of anti-GD2 CAR macrophages from human pluripotent stem cells for cancer immunotherapies","volume":"18","author":"Zhang","year":"2023","journal-title":"Stem Cell Reports"},{"key":"2026050410150952000_14.5.e014592.77","doi-asserted-by":"crossref","DOI":"10.3390\/cells11060994","article-title":"Ex vivo generation of CAR macrophages from hematopoietic stem and progenitor cells for use in cancer therapy","volume":"11","author":"Paasch","year":"2022","journal-title":"Cells"},{"key":"2026050410150952000_14.5.e014592.78","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2020.06.014"},{"key":"2026050410150952000_14.5.e014592.79","doi-asserted-by":"publisher","DOI":"10.1038\/gt.2012.61"},{"key":"2026050410150952000_14.5.e014592.80","doi-asserted-by":"publisher","DOI":"10.1038\/nm952"},{"key":"2026050410150952000_14.5.e014592.81","doi-asserted-by":"crossref","first-page":"154952","DOI":"10.1016\/j.phymed.2023.154952","article-title":"Targeting different phenotypes of macrophages: a potential strategy for natural products to treat inflammatory bone and joint diseases","volume":"118","author":"Gao","year":"2023","journal-title":"Phytomedicine"},{"key":"2026050410150952000_14.5.e014592.82","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1021\/acsbiomaterials.1c01532","article-title":"In vitro engineering chimeric antigen receptor macrophages and T cells by lipid nanoparticle-mediated mRNA delivery","volume":"8","author":"Ye","year":"2022","journal-title":"ACS Biomater Sci Eng"},{"key":"2026050410150952000_14.5.e014592.83","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19486-2"},{"key":"2026050410150952000_14.5.e014592.84","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.stem.2024.04.012","article-title":"Activating innate immune responses repolarizes hPSC-derived CAR macrophages to improve anti-tumor activity","volume":"31","author":"Shen","year":"2024","journal-title":"Cell Stem Cell"},{"key":"2026050410150952000_14.5.e014592.85","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.36688","article-title":"Chimeric antigen receptors that trigger phagocytosis","volume":"7","author":"Morrissey","year":"2018","journal-title":"Elife"},{"key":"2026050410150952000_14.5.e014592.86","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-04479-8"},{"key":"2026050410150952000_14.5.e014592.87","doi-asserted-by":"crossref","unstructured":"Greiner D , Xue Q , Waddell TQ , et al . CSPG4-targeting car-macrophages inhibit melanoma growth. Cancer Biology [Preprint]. doi:10.1101\/2024.06.04.597413","DOI":"10.1101\/2024.06.04.597413"},{"key":"2026050410150952000_14.5.e014592.88","doi-asserted-by":"crossref","DOI":"10.1007\/s00262-024-03759-6","article-title":"Engineered CD147-CAR macrophages for enhanced phagocytosis of cancers","volume":"73","author":"Chupradit","year":"2024","journal-title":"Cancer Immunol Immunother"},{"key":"2026050410150952000_14.5.e014592.89","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1186\/s10020-024-00996-4","article-title":"Leveraging CAR macrophages targeting c-Met for precision immunotherapy in pancreatic cancer: insights from single-cell multi-omics","volume":"30","author":"Hu","year":"2024","journal-title":"Mol Med"},{"key":"2026050410150952000_14.5.e014592.90","doi-asserted-by":"crossref","unstructured":"Pierini S , Klichinsky M , Gabbasov R , et al . 139\u2005Chimeric antigen receptor macrophages (car-m) elicit a systemic anti-tumor immune response and synergize with pd1 blockade in immunocompetent mouse models of her2+ solid tumors. SITC 36th Anniversary Annual Meeting (SITC 2021) Abstracts; November 2021 doi:10.1136\/jitc-2021-SITC2021.139","DOI":"10.1136\/jitc-2021-SITC2021.139"},{"key":"2026050410150952000_14.5.e014592.91","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/s41591-025-03495-z","article-title":"CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial","volume":"31","author":"Reiss","year":"2025","journal-title":"Nat Med"},{"key":"2026050410150952000_14.5.e014592.92","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2024.03.018"},{"key":"2026050410150952000_14.5.e014592.93","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-024-07267-4","article-title":"Inhibition of furin in CAR macrophages directs them toward a proinflammatory phenotype and enhances their antitumor activities","volume":"15","author":"Ziane-Chaouche","year":"2024","journal-title":"Cell Death Dis"},{"key":"2026050410150952000_14.5.e014592.94","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2023.07.021"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2025-014592","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T17:15:28Z","timestamp":1777914928000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2025-014592"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":94,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5,4]]},"published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1136\/jitc-2025-014592"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2025-014592","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]}}}